-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Oruka Therapeutics, Raises Price Target to $45

Benzinga·01/13/2026 13:48:40
Listen to the news
Wedbush analyst Martin Fan maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and raises the price target from $42 to $45.